Lipid effects of psychiatric medications
Junzo Watanabe1, Yutaro Suzuki, Toshiyuki Someya
1Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, 757 Asahimachidori-ichibancho, Chuo-ku, Niigata, 951-8510, Japan. junzo-w@umin.net
Insights
Patients with schizophrenia face higher risks of cardiovascular disease, often linked to dyslipidemia from antipsychotic medications. Regular fasting lipid measurements are crucial for managing these risks in schizophrenia patients.
Area of Science:
- Psychiatry
- Cardiology
- Pharmacology
Background:
- Schizophrenia patients experience elevated medical illness and mortality rates.
- Cardiovascular disease is a primary cause of premature death in schizophrenia.
- Dyslipidemia is a significant risk factor for cardiovascular disease, prevalent in schizophrenia.
Purpose of the Study:
- To highlight the link between second-generation antipsychotic agents and dyslipidemia.
- To discuss the association of depression with cardiovascular risks.
- To recommend strategies for reducing cardiovascular disease risk in schizophrenia patients.
Main Methods:
- Literature review on dyslipidemia and cardiovascular disease in schizophrenia.
- Analysis of the impact of antipsychotic agents on lipid profiles.
- Examination of depression's role in cardiovascular health.
Main Results:
- Second-generation antipsychotics are associated with a high prevalence of dyslipidemia.
- Depression correlates with increased risks of diabetes, hypertension, and cardiovascular disease.
- Antidepressant effects on lipid profiles require further investigation.
Conclusions:
- Fasting lipid measurements are essential for monitoring schizophrenia patients on antipsychotics.
- Proactive cardiovascular risk management is needed for this population.
- Further research is warranted on antidepressant effects on lipid profiles.
Abstract:
People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Psychosis and Antipsychotic Drugs: Overview
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Lipid-Lowering Drugs: Statins and Miscellaneous Agents


